Condition: Drug Resistant Epilepsy · Epilepsy · Seizures, Focal · Sponsor: NaviFUS Corporation
This will be a prospective, open-label, single-arm, multi-center, pilot study to evaluate the safety, tolerability, and preliminary efficacy of low-intensity focused ultrasound (LIFU) neuromodulation using NaviFUS System in patients with drug-resistant unilateral or bilateral temporal lobe epilepsy (DR-TLE).
This description comes directly from the study's public registry record.
Sheang-Tze Fung, Ph.D. · 02-25860560 · stfung@navifus.com
Arthur Lung, Ph.D. · arthur.lung@navifus.com
Always discuss trial participation with your own doctor first.
| Stanford University School of Medicine | Palo Alto, California, United States | Recruiting |
| Brigham and Women's Hospital | Boston, Massachusetts, United States | Recruiting |
| University of Virginia School of Medicine | Charlottesville, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06388707